# An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

> **NCT06987851** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 44 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Divozilimab

## Key facts

- **NCT ID:** NCT06987851
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-22
- **Primary completion:** 2024-05-16
- **Final completion:** 2024-05-16
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987851, "An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06987851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*